A potent human neutralizing antibody Fc-dependently reduces established HBV infections

A potent human neutralizing antibody Fc-dependently reduces established HBV infections

Hepatitis B virus (HBV) infection is a major global health problem. Currently-available therapies are ineffective in curing chronic HBV infection. HBV and its satellite hepatitis D virus (HDV) infect hepatocytes via binding of the preS1 domain of its large envelope protein to sodium taurocholate cot...

Full description

Bibliographic Details
Main Authors:	Dan Li, Wenhui He, Ximing Liu, Sanduo Zheng, Yonghe Qi, Huiyu Li, Fengfeng Mao, Juan Liu, Yinyan Sun, Lijing Pan, Kaixin Du, Keqiong Ye, Wenhui Li, Jianhua Sui
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2017-09-01
Series:	eLife
Subjects:	HBV NTCP preS1 antibody Fc receptor effector function
Online Access:	https://elifesciences.org/articles/26738

Similar Items

Tyrosine 146 of the Human Na<sup>+</sup>/Taurocholate Cotransporting Polypeptide (NTCP) Is Essential for Its Hepatitis B Virus (HBV) Receptor Function and HBV Entry into Hepatocytes
by: Dariusz Zakrzewicz, et al.
Published: (2022-06-01)

Key Factors for “Fishing” NTCP as a Functional Receptor for HBV and HDV
by: Huan Yan, et al.
Published: (2023-02-01)

Exploring the tolerable region for HiBiT tag insertion in the hepatitis B virus genome
by: Asako Murayama, et al.
Published: (2024-10-01)

The Culprit Behind HBV-Infected Hepatocytes: NTCP
by: Li S, et al.
Published: (2024-10-01)

Regulation of the HBV Entry Receptor NTCP and its Potential in Hepatitis B Treatment
by: Yan Li, et al.
Published: (2022-04-01)

Na<sup>+</sup>-Taurocholate Co-Transporting Polypeptide (NTCP) in Livers, Function, Expression Regulation, and Potential in Hepatitis B Treatment
by: Xiaoyu Zhao, et al.
Published: (2021-11-01)

IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection
by: Massimo Palatini, et al.
Published: (2022-03-01)

Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
by: Shamus P. Keeler, et al.
Published: (2021-05-01)

Understanding Fc function for rational vaccine design against pathogens
by: Kathryn A. Bowman, et al.
Published: (2024-01-01)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
by: Cheng Lei, et al.
Published: (2018-10-01)

Genomic characteristics of 12 HBV-I strains in the 2020 national HBV serosurvey in China
by: Qiudong Su, et al.
Published: (2025-02-01)

With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process
by: Silvia Crescioli, et al.
Published: (2025-12-01)

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
by: Bruce D. Wines, et al.
Published: (2022-07-01)

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines
by: Inna Tulaeva, et al.
Published: (2024-09-01)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
by: Bruce D. Wines, et al.
Published: (2023-01-01)

Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions
by: Elie Richel, et al.
Published: (2023-10-01)

Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses
by: Chisa Kobayashi, et al.
Published: (2022-04-01)

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions
by: Angela I. Schriek, et al.
Published: (2022-05-01)

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions
by: Angela I. Schriek, et al.
Published: (2022-11-01)

Engineered Fc-glycosylation switch to eliminate antibody effector function
by: Qun Zhou, et al.
Published: (2020-01-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)

The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles
by: Bingfu Jiang, et al.
Published: (2020-08-01)

Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
by: Sai Priya Anand, et al.
Published: (2019-08-01)

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA
by: Andréa Cottignies-Calamarte, et al.
Published: (2023-02-01)

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants
by: Robert Pejchal, et al.
Published: (2023-08-01)

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors
by: Michael Kirstgen, et al.
Published: (2021-04-01)

Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques
by: Marina Tuyishime, et al.
Published: (2023-12-01)

The Hepatitis B Virus PreS1/HBsAg Ratio Is a Predictive Marker for the Occurrence of Hepatocellular Carcinoma
by: Masanari Kosaka, et al.
Published: (2024-08-01)

Multitasking Na<sup>+</sup>/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery
by: Dariusz Zakrzewicz, et al.
Published: (2022-01-01)

HBV Pre-S1-Derived Myristoylated Peptide (Myr47): Identification of the Inhibitory Activity on the Cellular Uptake of Lipid Nanoparticles
by: Masaya Nanahara, et al.
Published: (2021-05-01)

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
by: Lili Wang, et al.
Published: (2023-12-01)

Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies
by: Yanchun Li, et al.
Published: (2024-04-01)

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance
by: DC Whitacre, et al.
Published: (2020-02-01)

The feasibility of establishing a hamster model for HBV infection: in vitro evidence
by: Hu Zhang, et al.
Published: (2024-11-01)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
by: Takuo Suzuki, et al.
Published: (2021-01-01)

Hepatitis B virus-targeting sodium taurocholate cotransporting polypeptide mediates HBV infection and damage in human renal podocytes
by: Lifen Wang, et al.
Published: (2024-03-01)

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Editorial: New functional separation and analysis technologies utilizing human Fc receptors
by: Tilman Schlothauer, et al.
Published: (2024-06-01)

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors
by: Geoff Hale, et al.
Published: (2024-12-01)

Upregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entry
by: Camillo Sargiacomo, et al.
Published: (2017-09-01)